The minimal active domain of endostatin is a heparin-binding motif that mediates inhibition of tumor vascularization

Cancer Research

Volumn 64, Issue 24, 2004, Pages 9012-9017

  Olsson, Anna Karin ^a,d   Johansson, Irja ^a   Åkerud, Helena ^a   Einarsson, Barbro ^b   Christofferson, Rolf ^b   Sasaki, Takako ^c   Timpl, Rupert ^c   Claesson Welsh, Lena ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ARGININE DERIVATIVE; COLLAGEN; COLLAGEN XVIII; ENDOSTATIN; FIBROBLAST GROWTH FACTOR 2; HEPARIN; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; VASCULOTROPIN A;

AMINO ACID SUBSTITUTION; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CHEMOTAXIS; CHICKEN; CHORIOALLANTOIS; CONTROLLED STUDY; DELETION MUTANT; DRUG BINDING SITE; DRUG MECHANISM; FEMALE; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN MOTIF; STRUCTURE ACTIVITY RELATION; TUMOR VASCULARIZATION;

AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; CATTLE; CHEMOTAXIS; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; ENDOSTATINS; ENDOTHELIUM, VASCULAR; FEMALE; FIBROBLAST GROWTH FACTOR 2; FIBROSARCOMA; HEPARIN; HUMANS; MICE; MICE, INBRED C57BL; MICE, SCID; MOLECULAR SEQUENCE DATA; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PANCREATIC NEOPLASMS; PEPTIDE FRAGMENTS; PROTEIN STRUCTURE, TERTIARY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 10844296760     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-2172     Document Type: Article

References (37)

1. Risau W. Mechanisms of angiogenesis. Nature (Lond) 1997;386:671-4.
2. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
3. Folkman, J. Tumor angiogenesis. In: Holland JF, Frei EI, Bast RCJ, Kufe DW, Pollock RE, Weichselbaum RR, editors. Cancer Medicine, 5th edition, Ontario, Canada: B. C. Decker Inc; 2000. p. 132-52.
4. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
5. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature (Lond) 2000;407:249-257.
6. Cross MJ, Claesson-Welsh L. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 2001;22:201-7.
7. Javerzat S, Auguste P, Bikfalvi A. The role of fibroblast growth factors in vascular development. Trends Mol Med 2002;8:483-9.
8. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76.
9. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-85.
10. Dixelius J, Cross MJ, Matsumoto T, Claesson-Welsh L. Endostatin action and intracellular signaling: beta-catenin as a potential target? Cancer Lett 2003;196:1-12.
11. Ma L, Elliott SN, Cirino G, Buret A, Ignarro LJ, Wallace JL. Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release. Proc Natl Acad Sci USA 2001;98:6470-5.
12. Miosge N, Sasaki T, Timpt R. Angiogenesis inhibitor endostatin is a distinct component of elastic fibers in vessel walls. FASEB J 1999;13:1743-50.
13. Sasaki T, Fukai N, Mann K, Gohring W, Olsen BR, Timpl R. Structure, function and tissue forms of the C-terminal globular domain of collagen XVIII containing the angiogenesis inhibitor endostatin. EMBO J 1998;17:4249-56.
14. Yu Y, Moulton KS, Khan MK, et al. E-selectin is required for the antiangiogenic activity of endostatin. Proc Natl Acad Sci USA 2004;101:8005-10.
15. Sasaki T, Larsson H, Kreuger J, et al. Structural basis and potential role of heparin/heparan sulfate binding to the angiogenesis inhibitor endostatin. EMBO J 1999;18:6240-8.
16. Karumanchi SA, Jha V, Ramchandran R, et al. Cell surface glypicans are low-affinity endostatin receptors. Mol Cell 2001;7:811-22.
17. Rehn M, Veikkola T, Kukk-Valdre E, et al. Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci USA 2001;98:1024-9.
18. Wickström SA, Alitalo K, Keski-Oja J. Endostatin associates with integrin alpha5beta1 and caveolin-1, and activates Src via a tyrosyl phosphatase-dependent pathway in human endothelial cells. Cancer Res 2002;62:5580-9.
19. Wickström SA, Alitalo K, Keski-Oja J. Endostatin associates with lipid rafts and induces reorganization of the actin cytoskeleton via down-regulation of RhoA activity. J Biol Chem 2003;278:37895-901.
20. Sudhakar A, Sugimoto H, Yang C, Lively J, Zeisberg M, Kalluri R. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proc Natl Acad Sci USA 2003;100:4766-71.
21. Dixelius J, Larsson H, Sasaki T, et al. Endostatin-induced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis. Blood 2000;95:3403-11.
22. Yamaguchi N, Anand-Apte B, Lee M, et al. Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J 1999;18:4414-23.
23. Hohenester E, Sasaki T, Olsen BR, Timpl R. Crystal structure of the angiogenesis inhibitor endostatin at 1.5 A resolution. EMBO J 1998;17:1656-64.
24. Kreuger J, Matsumoto T, Vanwildemeersch M, et al. Role of heparan sulfate domain organization in endostatin inhibition of endothelial cell function. EMBO J 2002;21:6303-11.
25. Vallejo AN, Pogulis RJ, Pease LR. In vitro synthesis of novel genes: mutagenesis and recombination by PCR. PCR Methods Appl 1994;4:S123-130.
26. Poschl E, Mayer U, Stetefeld J, et al. Site-directed mutagenesis and structural interpretation of the nidogen binding site of the laminin gamma1 chain. EMBO J 1996;15:5154-9.
27. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA. Definition of two angiogenic pathways by distinct alpha v integrins. Science (Lond) 1995;270:1500-2.
28. Auerbach R, Auerbach W, Polakowski I. Assays for angiogenesis: a review. Pharmacol Ther 1991;51:1-11.
29. Workman P, Balmain A, Hickman JA, et al. UKCCCR guidelines for the welfare of animals in experimental neoplasia. Lab Anim 1988;22:195-201.
30. Gundersen HJ, Bendtsen TF, Korbo L, et al. Some new, simple and efficient stereological methods and their use in pathological research and diagnosis. Apmis 1988;96:379-94.
31. Olsson AK, Larsson H, Dixelius J, et al. A fragment of histidine-rich glycoprotein is a potent inhibitor of tumor vascularization. Cancer Res 2004;64:599-605.
32. Kisker O, Becker CM, Prox D, et al. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res 2001;61:7669-74.
33. Sasaki T, Larsson H, Tisi D, et al. Endostatins derived from collagens XV and XVIII differ in structural and binding properties, tissue distribution and anti-angiogenic activity. J Mol Biol 2000;301:1179-90.
34. Wickström SA, Alitalo K, Keski-Oja J. An endostatin-derived peptide interacts with integrins and regulates actin cytoskeleton and migration of endothelial cells. J Biol Chem 2004;279:20178-85.
35. Cattaneo MG, Pola S, Francescato P, Chillemi F, Vicentini LM. Human endostatin-derived synthetic peptides possess potent antiangiogenic properties in vitro and in vivo. Exp Cell Res 2003;283:230-6.
36. Chillemi F, Francescato P, Ragg E, Cattaneo MG, Pola S, Vicentini L. Studies on the structure-activity relationship of endostatin: synthesis of human endostatin peptides exhibiting potent antiangiogenic activities. J Med Chem 2003;46:4165-72.
37. Morbidelli L, Donnini S, Chillemi F, Giachetti A, Ziche M. Angiosuppressive and angiostimulatory effects exerted by synthetic partial sequences of endostatin. Clin Cancer Res 2003;9:5358-69.